ADBE
Adobe Inc.
ADBE has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
ADBE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ADBE's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADBE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.9x | $239 | — |
| Current | 13x | $239 | — |
| Cheap | 22x | $396 | +66% |
| Fair | 43x | $771 | +223% |
| Expensive | 54x | $972 | +308% |
Historical ranges are pointers, not guarantees.
ADBE's PE is in its cheap range at 13x. If earnings grow as analysts expect, today's price would be 8.9x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ADBE in the historical PE scenario, which offers more potential upside but is not a forecast.
ADBE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for ADBE, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ADBE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.84 | +50% |
| Q3 2026 | $17.91 | +12% |
| Q2 2026 | $17.47 | +12% |
| Q1 2026 | $17.16 | +13% |
| Q4 2025 | $16.70 | +35% |
| Q3 2025 | $16.01 | +35% |
| Q2 2025 | $15.59 | +40% |
| Q1 2025 | $15.14 | +45% |
| Q4 2024 | $12.36 | +4.6% |
ADBE has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ADBE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.8B | +13% |
| Q2 2026 | $6.6B | +13% |
| Q1 2026 | $6.4B | +12% |
| Q4 2025 | $6.2B | +10% |
| Q3 2025 | $6B | +11% |
| Q2 2025 | $5.9B | +11% |
| Q1 2025 | $5.7B | +10% |
| Q4 2024 | $5.6B | +11% |
ADBE's revenue has grown year over year every quarter since late 2020: $6.8B last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -1.5 points |
| Q2 2026 | 34% | -2.1 points |
| Q1 2026 | 38% | -0.1 points |
| Q4 2025 | 37% | +1.6 points |
| Q3 2025 | 36% | -0.5 points |
| Q2 2025 | 36% | +0.4 points |
| Q1 2025 | 38% | +20 points |
| Q4 2024 | 35% | +0.4 points |
ADBE has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ADBE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ADBE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.4B | +15% |
| Q2 2026 | $2.1B | -1.7% |
| Q1 2026 | $2.9B | +19% |
| Q4 2025 | $3.1B | +8.8% |
| Q3 2025 | $2.1B | +8.2% |
| Q2 2025 | $2.1B | +13% |
| Q1 2025 | $2.5B | +116% |
| Q4 2024 | $2.9B | +85% |
ADBE has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ADBE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -7M shares |
| 1 year | -6.7% | -28.6M shares |
| 3 years | -14% | -64M shares |
| 5 years | -18% | -85.2M shares |
| Available history | -20% | -96.1M shares |
ADBE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.2B |
| Q2 2026 | $2.1B |
| Q1 2026 | $2.5B |
| Q4 2025 | $2.5B |
| Q3 2025 | $2.1B |
| Q2 2025 | $3.5B |
| Q1 2025 | $3.3B |
| Q4 2024 | $2.5B |
ADBE spent $9.3B buying back its own shares over the past year, down 18% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ADBE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
ADBE's net debt is less than a year of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ADBE on leverage, with a lower net debt burden relative to earnings.
ADBE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 25.8 | Neutral |
ADBE's weekly RSI is 45 (neutral) and its Stochastic is 26 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ADBE PE vs Technology Sector
| Metric | ADBE | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 28x | 52% below |
| PE % | 3 | 35 | 32 pts below |
ADBE has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ADBE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $244.1 | 2.3% below |
| 20 week MA | $248.6 | 4.1% below |
| 50 week MA | $261.6 | 8.8% below |
| 100 week MA | $321.8 | 26% below |
| 200 week MA | $410.6 | 42% below |
ADBE is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ADBE on trend strength, trading above more of its moving averages.
ADBE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.8 | $499.9 | +51% |
| 2021 | $499.9 | $569.6 | +14% |
| 2022 | $569.6 | $338.5 | -41% |
| 2023 | $338.5 | $596.6 | +76% |
| 2024 | $596.6 | $446.5 | -25% |
| 2025 | $446.5 | $353.8 | -21% |
| 2026 YTD | $353.8 | $238.5 | -33% |
ADBE has finished lower in three of the last six years. It's down 33% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ADBE on returns for 2026, with the stronger performance.